# A common polymorphism in the human immunoreceptor NKp65 determines ligand interaction, cell surface expression and function

**Authors:** Julian Leonard Lino Heller, Yvonne Bartel, Catalin Schach, Angelina Kirsten, Felicitas Schlatter, Alexander Steinle

PMC · DOI: 10.1371/journal.pone.0329454 · PLOS One · 2025-08-13

## TL;DR

A common genetic variation in the NKp65 receptor affects its surface expression, ligand binding, and ability to trigger cell-killing activity in immune cells.

## Contribution

The study reveals how a specific polymorphism in NKp65 alters its function and may influence immune responses in the skin.

## Key findings

- The Thr131 variant of NKp65 is weakly expressed on the cell surface due to intracellular retention.
- The polymorphism reduces binding affinity to the ligand KACL and impairs cytotoxic activity.
- The rs576601 polymorphism may affect skin immunosurveillance by NKp65-expressing ILC3 cells.

## Abstract

The human immunoreceptor NKp65 is specifically expressed by a subset of human innate lymphocytes, i.e., innate lymphoid cells group 3 (ILC3) and activates cellular cytotoxicity upon interaction with its genetically linked ligand KACL. In the context of the present study, the relevance of a common polymorphism in the NKp65-coding KLRF2 gene was addressed.

Using biophysical methods such as flow cytometry and surface resonance spectroscopy, as well as immunological methods such as ELISA and immunoblots and cytotoxicity assays, the influence of polymorphism rs576601 on surface expression, binding kinetics to the ligand KACL, proteolytic cleavage, intracellular retention, and functional responsiveness of NKp65 was investigated.

Polymorphism rs576601 entails the exchange of cytosine for adenine, resulting in a substitution of proline by threonine at amino acid position 131 within the C-type lectin-like ectodomain of NKp65. Here, we show that the NKp65-Thr131 variant is only weakly expressed on the cell surface as compared to the NKp65-Pro131 variant. This is due to an enhanced intracellular retention of NKp65-Thr131 but not due to proteolytic cleavage. In addition, the polymorphism rs576601 has a significant impact on the binding kinetics and affinity to the ligand KACL. On a functional level, the combination of reduced surface expression and affinity resulted in a drastically reduced cellular cytotoxicity of NKp65-Thr131+ effector cells towards KACL+ target cells.

The polymorphism rs576601 affects ligand interaction, cell surface expression and function of NKp65. Since the NKp65 ligand KACL is primarily expressed on keratinocytes, polymorphism rs576601 may impact on skin immunosurveillance by NKp65-expressing ILC3.

## Linked entities

- **Genes:** KLRF2 (killer cell lectin like receptor F2) [NCBI Gene 100431172]
- **Proteins:** KLRF2 (killer cell lectin like receptor F2), CLEC2A (C-type lectin domain family 2 member A)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** GLS (glutaminase) [NCBI Gene 2744] {aka AAD20, CASGID, DEE71, EIEE71, GAC, GAM}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, SYK (spleen associated tyrosine kinase) [NCBI Gene 6850] {aka IMD82, p72-Syk}, ADM2 (adrenomedullin 2) [NCBI Gene 79924] {aka AM2, dJ579N16.4}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, KIR2DL5A (killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5A) [NCBI Gene 57292] {aka CD158F, KIR2DL5, KIR2DL5.1, KIR2DL5.3}, KLRF2 (killer cell lectin like receptor F2) [NCBI Gene 100431172] {aka NKp65}, KLRF1 (killer cell lectin like receptor F1) [NCBI Gene 51348] {aka CLEC5C, NKp80}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, CLEC2A (C-type lectin domain family 2 member A) [NCBI Gene 387836] {aka INPE5792, KACL, PILAR, UNQ5792}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MANEA (mannosidase endo-alpha) [NCBI Gene 79694] {aka ENDO, hEndo}
- **Diseases:** Xeroderma pigmentosum (MESH:D014983), psoriatic disease (MESH:D015535), squamous cell carcinoma (MESH:D002294), inflammatory skin diseases (MESH:D012871), Cytotoxicity (MESH:D064420)
- **Chemicals:** threonine (MESH:D013912), E (MESH:D004540), glycan (MESH:D011134), Ni-NTA (MESH:C088321), phosphoric acid (MESH:C030242), NP40 (MESH:C010615), SA- (MESH:D000077145), Tween (MESH:D011136), Stop (MESH:D014002), agarose (MESH:D012685), sulfate (MESH:D013431), Saponin (MESH:D012503), polybrene (MESH:D006583), SDS (MESH:D012967), PVDF (MESH:C024865), mannose (MESH:D008358), DOX (MESH:D004318), AMPHO (-), 3,3',5,5'-Tetramethylbenzidine (MESH:C021758), valine (MESH:D014633), PEI (MESH:D011094), Proline (MESH:D011392), T (MESH:D014316), CO2 (MESH:D002245), isoleucine (MESH:D007532)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** cytosine for adenine, C in 500, threonine (Thr) at position 131, valine (Val) at position 68, C with 100, cytosine for adenine
- **Cell lines:** 293-F — Homo sapiens (Human), Transformed cell line (CVCL_6642), 293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), AML01 — Homo sapiens (Human), Adult acute myeloid leukemia, Cancer cell line (CVCL_1619), 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), NK92-MI — Homo sapiens (Human), Natural killer cell lymphoblastic leukemia/lymphoma, Cancer cell line (CVCL_3755), NK92 — Homo sapiens (Human), Natural killer cell lymphoblastic leukemia/lymphoma, Cancer cell line (CVCL_2142), U937 — Homo sapiens (Human), Adult acute monocytic leukemia, Cancer cell line (CVCL_0007), CEM.NKR — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_X622)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12349009/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12349009/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12349009/full.md

---
Source: https://tomesphere.com/paper/PMC12349009